Overview
Pharmaceutical

RIBOMIC Inc.

RiboMic is a Japanese biopharmaceutical company specializing in the research and development of aptamer-based medicines (a form of nucleic acid drug), positioning aptamers as next-generation therapeutics following antibody drugs. The company leverages its proprietary drug discovery platform, 'RiboART System®', to design and develop innovative aptamer drug candidates targeting unmet medical needs. Its lead asset, umedaptanib pegol (RBM-007), an anti-FGF2 aptamer, is currently in clinical development for achondroplasia (a rare skeletal dysplasia) and wet age-related macular degeneration (wet AMD).

Market Cap
¥3.73B
US$23.8M
EV
¥0.95B
US$6.07M
Stock¥66▲+1.54%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
1.4
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-49.6%pt
1001
Oct 24, 25 – Oct 23, 26StockTOPIX
1Mar 4, 26Market-wide: TOPIX -3.7% decline
MC → EV Bridge
3.73BUS$23.8MMarket Cap0.00BUS$0.00M+ Debt1.98BUS$12.6M− Cash0.80BUS$5.10M− Inv. Sec.0.95BUS$6.07MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.08US$0.51M'22/30.07US$0.41M'23/30.35US$2.24M'24/30.00US$0.01M'25/30.00US$0.02M'26/3
EBITDA 5Y (¥B)
-1.73-US$11.0M'22/3-1.79-US$11.4M'23/3-1.11-US$7.05M'24/3-1.05-US$6.69M'25/3-1.20-US$7.67M'26/3
Net Income 5Y (¥B)
-1.68-US$10.7M'22/3-1.65-US$10.5M'23/3-1.02-US$6.53M'24/3-1.02-US$6.49M'25/3-1.15-US$7.30M'26/3
Capital Structure
100%
EquityD/E 0.00xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
2.90US$18.5M'22/32.83US$18.0M'23/32.10US$13.4M'24/31.84US$11.7M'25/31.93US$12.3M'26/3
Shareholders
Top 10 hold 13.2%
1
BNP PARIBAS LONDON BRANCH FOR PRIME BROKERAGE CLEARANCE ACC FOR THIRD PARTY (Standing Proxy: The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)
2.82%
2
BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC; Standing Proxy: MUFG Bank, Ltd.)
1.82%
3
MATSUI SECURITIES CO.,LTD.
1.57%
4
UBS AG LONDON A/C IPB SEGREGATED CLIENT ACCOUNT (Standing Proxy: Citibank, N.A., Tokyo Branch)
1.16%
5
Daiwa Securities Co. Ltd.
1.10%
6
Zenyaku Kogyo Co., Ltd.
1.06%
7
Yoshikazu NAKAMURA
1.04%
8
Rakuten Securities, Inc. (Joint Account)
0.99%
9
Hideyuki YUASA
0.92%
10
SBI SECURITIES Co., Ltd.
0.72%
Management
7 officers
Yoshikazu NAKAMURA
Representative Director, President and Head of Business Promotion Division
Apr 1978 Assistant Professor, Institute of Medical Science, University of Tokyo Jun 1986 Associate Professor, Institute of Medical Science, University of Tokyo Oct 2000 Professor, Institute of Medical Science, University of Tokyo Oct 2005 Director, Chief Technology Officer and Founder, RIBOMIC Inc. Apr 2012 Representative Director, President, RIBOMIC Inc. Jun 2012 Professor Emeritus, University of Tokyo (current) Aug 2017 Director, RIBOMIC USA Inc. (current) Jun 2020 Representative Director, President and Head of Research and Development Division, RIBOMIC Inc. Oct 2020 Representative Director, President, RIBOMIC Inc. Sep 2022 President and CEO, RIBOMIC USA Inc. (current) Feb 2023 Representative Director, President and Head of Research and Development Division, RIBOMIC Inc. Apr 2023 Representative Director, President, RIBOMIC Inc. Apr 2024 Representative Director, President and Head of Business Promotion Division, RIBOMIC Inc. (current) Feb 2026 Director, Medical Science Research Promotion Foundation (current)
1947-11-25
Kenro ADACHI
Director, Executive Officer and Head of Research and Development Division
Apr 2012 Research Fellow (DC1), Japan Society for the Promotion of Science Dec 2016 Joined RIBOMIC Inc. Dec 2018 Chief Researcher, RIBOMIC Inc. May 2021 Executive Officer and Head of Exploratory Research Department, RIBOMIC Inc. Oct 2023 Executive Officer, Head of Research and Development Division and Head of Exploratory Research Department, RIBOMIC Inc. Jun 2024 Director, Executive Officer, Head of Research and Development Division and Head of Exploratory Research Department, RIBOMIC Inc. Apr 2025 Director, Executive Officer and Head of Research and Development Division, RIBOMIC Inc. (current)
1987-08-14
Chiya MATSUFUJI
Director
Mar 1989 Completed Doctoral Program, Jikei University School of Medicine; Doctor of Medicine Apr 1989 Assistant, Department of Nutrition, Jikei University School of Medicine Oct 1992 Study Abroad, University of Utah Institute of Human Genetics and Howard Hughes Medical Institute, USA Nov 1996 Associate Professor, Second Department of Biochemistry, Jikei University School of Medicine Mar 2001 Professor, Jikei University School of Medicine May 2007 Professor in Charge, Department of Molecular Biology, Jikei University School of Medicine Apr 2013 President, Jikei University School of Medicine; Director, The Jikei University School Corporation (current) Jun 2021 Director, RIBOMIC Inc. (current)
1958-07-04
Toshinobu FUJIWARA
Director
Feb 2003 Assistant Professor, Graduate School of Science and Technology, Kobe University Apr 2006 Researcher (concurrent), PRESTO, Japan Science and Technology Agency Apr 2007 Associate Professor, Department of Applied Chemistry, Graduate School of Engineering, Kobe University Apr 2011 Senior Researcher, Institute of Microbial Chemistry Apr 2011 Visiting Associate Professor (concurrent), Immunology Frontier Research Center, Osaka University Apr 2013 Professor, Department of Hygienic Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University Apr 2013 Visiting Professor (concurrent), Immunology Frontier Research Center, Osaka University Apr 2015 Professor, Laboratory of Biochemistry, Faculty of Pharmacy, Kindai University (current) Oct 2022 Dean, Graduate School of Pharmaceutical Sciences, Kindai University (current) Jun 2023 Director, RIBOMIC Inc. (current)
1972-10-04
Toshiaki NISHIHATA
Director (Audit and Supervisory Committee Member)
Mar 1979 Research Assistant, Faculty of Pharmaceutical Sciences, Osaka University Apr 1981 Associate Professor, University of Kansas Jun 1988 Joined Upjohn Pharmaceuticals Ltd. (now Pfizer Inc.) Mar 1996 Joined Santen Pharmaceutical Co., Ltd. Jul 1999 Executive Officer, Santen Pharmaceutical Co., Ltd. Dec 2002 Executive Officer and Head of Research and Development Division, Santen Pharmaceutical Co., Ltd. Jul 2004 Managing Executive Officer and Head of Research and Development Division, Santen Pharmaceutical Co., Ltd. Jun 2009 Director, Managing Executive Officer and Head of Research and Development Division, Santen Pharmaceutical Co., Ltd. Apr 2010 Director, President and CEO, Santen Inc. (concurrent) Apr 2011 Director, Senior Managing Executive Officer, in charge of U.S. and European Businesses and Head of Research and Development Division, Santen Pharmaceutical Co., Ltd. Jul 2015 Advisor, RIBOMIC Inc. Jun 2016 Director (Audit and Supervisory Committee Member), RIBOMIC Inc. (current) Feb 2018 Outside Director, Trans Chromosomics, Inc.
1948-11-04
Mamoru YAMAMOTO
Director (Audit and Supervisory Committee Member)
Apr 1981 Joined Asahi & Co., Tokyo Office (now Ernst & Young ShinNihon LLC) Mar 1984 Registered as Certified Public Accountant May 1995 Appointed Partner (now Partner) May 2002 Appointed Representative Partner (now Partner) Jul 2018 Established Nihonbashi Accounting Service Co., Ltd.; Representative Director and President (current) Jul 2018 Director, E-Tai Co., Ltd. Dec 2018 Director, Abist Co., Ltd. Jun 2019 Audit & Supervisory Board Member, Cogent Labs, Inc. (current) Dec 2022 Director (Audit and Supervisory Committee Member), Abist Co., Ltd. (current) Dec 2024 Audit & Supervisory Board Member, Tsujimotogo IT Consulting Co., Ltd. (current)
1956-05-01
Makoto KAIAMI
Director (Audit and Supervisory Committee Member)
Apr 1978 Appointed Judge Apr 2000 Presiding Judge, Tokyo District Court Jul 2007 Senior Counsel for Litigation, Minister's Secretariat, Ministry of Justice Jul 2009 Judge, Tokyo High Court Dec 2009 Chief Judge, Wakayama District and Family Courts Jan 2011 Chief Judge, Nagano District and Family Courts Nov 2012 Presiding Judge, Tokyo High Court Jul 2014 Chief Judge, Tokyo Family Court Jun 2015 Chief Judge, Tokyo District Court Oct 2016 Retired upon reaching mandatory retirement age Feb 2017 Registered as Attorney-at-Law, Dai-Ichi Tokyo Bar Association Jun 2017 Outside Director, FUJIFILM Holdings Corporation Jun 2018 Outside Director, Tokyu Fudosan Holdings Corporation (current) Jun 2018 Outside Audit & Supervisory Board Member, Seiren Co., Ltd. (current) Sep 2018 Partner, Otemachi Law Office (current) Jun 2020 Outside Director, Japan Post Holdings Co., Ltd. (current)
1951-10-05
Large Shareholding Reports
Evo Fund
2026-06-22
29.29%→28.68%
Evo Fund
2026-06-03
30.35%→29.29%
Evo Fund
2026-05-13
30.83%→30.35%
Evo Fund
2026-04-24
30.83%→30.79%
Correction filing (name/detail fix only) — ratio carried over from the original filing
Evo Fund
2026-04-21
30.83%→30.79%
Evo Fund
2026-04-06
32.13%→30.83%
Evo Fund
2025-12-17
32.40%→32.13%
Evo Fund
2025-12-16
33.82%→32.40%
Evo Fund
2025-12-05
34.58%→33.82%
Evo Fund
2025-11-18
35.70%→34.58%
Evo Fund
2025-09-12
36.98%→35.70%
Evo Fund
2025-09-09
38.47%→36.98%
Evo Fund
2025-09-04
38.65%→38.47%
Evo Fund
2025-09-02
39.80%→38.65%
Evo Fund
2025-08-28
41.54%→39.80%
Evo Fund
2025-08-19
41.54%→41.54%
Evo Fund
2025-08-18
41.54%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-10-20
Forecast Revision
TDnet
2026-08-13
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-22
Large Shareholding Report
EDINET
2026-06-19
Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-06-03
Large Shareholding Report
EDINET
2026-05-13
Large Shareholding Report
EDINETAmended
2026-04-24
Change Report
EDINET
2026-04-21
Large Shareholding Report
EDINET
2026-04-06
Large Shareholding Report
TDnet
2026-02-12
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-12-17
Large Shareholding Report
EDINET
2025-12-16
Large Shareholding Report
EDINET
2025-12-05
Large Shareholding Report
EDINET
2025-11-18
Large Shareholding Report
EDINET
2025-11-12
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2025-09-12
Large Shareholding Report
EDINET
2025-09-09
Large Shareholding Report
EDINET
2025-09-04
Large Shareholding Report
EDINET
2025-09-02
Large Shareholding Report
EDINET
2025-08-28
Large Shareholding Report
EDINET
2025-08-19
Large Shareholding Report
EDINET
2025-08-18
Large Shareholding Report
TDnet
2025-08-12
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-07-23
Securities Registration Statement
EDINET
2025-06-20
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-12
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-13
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-09
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-26
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-14
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →